Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,257.49
(
0.67%
)
US TECH 100
27,017.60
(
1.15%
)
Dow Jones
49,698.67
(
0.09%
)
Brent Oil
106.81
(
-3.21%
)
Bitcoin
78,370.33
(
2.67%
)
News Focus
News Focus
Post# of 257479
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122921
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 203602

Thursday, 08/18/2016 10:45:40 AM

Thursday, August 18, 2016 10:45:40 AM

Post# of 257479
EARS tinnitus post-mortem: EARS never established PoC for Keyzilen (f/k/a AM-101) in phase-2; rather, they used post-hoc subset analysis to justify advancing Keyzilen to phase-3.

The second Keyzilen phase-3 trial (TACTT3) has a slightly different design from TACTT2 and is due to report results in a few months, but it’s very unlikely to succeed, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today